Skip to main content
OpenTrials
Completed

NCT Number: NCT05486195

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

This is a First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects including Receptor Occupancy Measurements after Single Dose of SDI-118 and an Assessment of Food Effect.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Disorders Cognition Disorders Cognitive Dysfunction Mental Disorders Neurocognitive Disorders

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Centre for Clinical Pharmacology, UZ Leuven

Leuven, B-3000, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects, 18 to 50 years of age, inclusive.
  • Non-smokers or abstinence from tobacco for at least 3 months prior to screening.
  • Body mass index (BMI) between 18 and 30 kg/m2, inclusive, with a minimum weight of 50 kg and maximum of 100 kg.
  • Venous access sufficient to allow blood sampling as per the protocol.
  • Agree to abstain from alcohol intake 24h before each administration of study drug, during the in-patient period of the study and 24 hours prior to all other out-patient clinic visits.
  • Have given written informed consent approved by the relevant Ethics Committee (EC) governing the site.
  • In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the clinical study protocol restrictions and requirements.
  • Subjects and their partners of childbearing potential must be willing to use 2 methods of contraception, one of which must be a barrier method, for the duration of the study and up to 90 days after the last dose.

Specifically, Part B/PET related inclusion criteria:

  • Adequate arterial circulation in both hands (Allen's test).
  • MRI scan without clinically significant abnormalities.

Specifically, Part C/FE related inclusion criteria:

  • Subjects are not vegetarian and willing to eat a standardized high fat breakfast including butter and bacon.

Exclusion criteria

  • History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal (GI), hepatic, or renal disorder.
  • Positive Hepatitis B surface antigen (HBs Ag), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
  • Use of any medications (prescription or over-the-counter (OTC)), vitamin, mineral, herbal, and dietary supplements (including grapefruit products) within 7 days of study drug administration, or less than 5 half-lives (whichever is longer).
  • Have an estimated Glomerular Filtration Rate (eGFR) <80 mL/min/1.73m2.

Any of the following findings in the resting ECG:

  • QTcF> 450 or < 300 msec at screening or baseline visit,
  • Notable resting bradycardia (HR < 40 bpm) or tachycardia (HR > 100 bpm) at screening or baseline visit,
  • Personal or family history of congenital long QT syndrome or sudden death,
  • Screening or baseline ECG with QRS and/or T wave judged to be unfavourable for a consistently accurate QT measurement (e.g. neuromuscular artefact that cannot be readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T- and U-waves, prominent U waves),
  • Evidence of atrial fibrillation, atrial flutter, Left Bundle Branch Block (LBBB), Wolf-Parkinson-White Syndrome, or cardiac pacemaker at screening or baseline visit (note: a first degree heart block with PR not exceeding 250 msec can be allowed).

Specifically, Part B/PET related exclusion criteria:

  • Previous inclusion in a research study and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden (a significant radiation burden being defined as International Commission on Radiological Protection (ICRP) category IIb or above: no more than 1 mSv in addition to the natural background radiation in the previous 12 months including the dose from the study).
  • Subject who fulfils any of the MRI contraindications on the standard radiography screening questionnaire (including the presence of ferromagnetic metal in the body or heart pacemaker).
  • History of or suffers from claustrophobia or feels that they will be unable to lie still on their back in the PET camera for a period of 2 hours.
  • Any known allergy to local anaesthetics or heparin.

Treatment and study plan

SDI-118

Drug

SDI-118 Powder in Capsule

Placebo

Drug

Matching Placebo

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: 21 Days

    Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a participant administered a study drug and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical product whether or not considered related to the medical product. An AE is considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event.

  2. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant laboratory values (hematology/chemistry/urinalysis)

  3. Number of participants with vital sign abnormalities and/or adverse events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant vital sign values

  4. Number of participants with temperature abnormalities and/or adverse events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant temperature values

  5. Number of participants with routine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant ECG values.

  6. Number of participants with routine physical examination abnormalities and/or Adverse Events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant changes in physical examination.

  7. Number of participants with routine neurological examination abnormalities and/or Adverse Events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant changes in neurological examination.

  8. Number of participants with abnormalities on Profile of Mood States (Brief) and/or Adverse Events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant changes in Profile of Mood States (Brief) values.

  9. Number of participants with abnormalities on Bond-Lader-VAS and/or Adverse Events (AEs)

    Time frame: 21 Days

    Number of participants with potentially clinically significant changes in Bond-Lader VAS values.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Collaborators

  • KU Leuven
  • Syndesi Therapeutics

Registry information

Official study title

A First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including Receptor Occupancy Measurements After Single Dose of SDI-118 and an Assessment of Food Effect

Important dates

Study start
2019
Primary completion
2019
Study completion
2020
First posted
Aug 3, 2022
Registry last updated
Aug 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.